Development of Delpazolid for the Treatment of Tuberculosis
Applied Sciences, 2020 A novel oxazolidinone with cyclic amidrazone, delpazolid (LCB01-0371), was synthesized by LegoChem BioSciences, Inc. (Daejeon, Korea). Delpazolid can improve the minimum bactericidal concentration of Mycobacterium tuberculosis H37Rv and significantly ...
Young Lag Cho, Jichan Jang
doaj +1 more source
Drug Repurposing for Tuberculosis [PDF]
, 2021 Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a major global health concern given the increase in multiple forms of drug-resistant TB. This underscores the importance of a continuous pipeline of new anti-TB agents.
Cardoso, Nicole C. +3 more
core +2 more sources
Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: A narrative review [PDF]
, 2023 Advancement in the area of anti-tubercular drug development has been full-fledged, yet, a very less number of drug molecules have reached phase II clinical trials, and therefore "End-TB" is still a global challenge.
Nagarajan, U, Natarajan, S, Sreelatha, S
core +4 more sources
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis:a 2023 TBnet/RESIST-TB consensus statement [PDF]
, 2023 Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis
core +4 more sources
Challenges and recent progress in drug discovery for tropical diseases [PDF]
, 2018 Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries. These diseases predominantly affect the world’s poorest people.
A Guidi +117 more
core +2 more sources
Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic [PDF]
, 2021 The WHO 2020 global TB Report estimates that in 2019 there were an estimated 500,000 cases of multi-drug resistant TB (MDR-TB) of which only 186,772 MDR-TB cases were diagnosed, and positive treatment outcomes were achieved in 57% of them.
Galvin, J +5 more
core
Accelerating the development of therapeutic strategies for drug-resistant tuberculosis [PDF]
, 2018 Recent progress in the discovery, development and evaluation of new drugs and combination regimens for drug-resistant tuberculosis through greater collaboration between industry, donors and academia provides renewed hope for overcoming the challenges in ...
Tiberi, S, Vjecha, MJ, Zumla, A
core +1 more source
Infection and Drug Resistance, 2023 Tianhui Gao,1,* Cong Yao,1,* Yuanyuan Shang,1 Renchun Su,1 Xuxia Zhang,1 Weicong Ren,1 Shanshan Li,1 Wei Shu,2 Yu Pang,1 Qi Li2 1Department of Bacteriology and Immunology, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Gao T +9 more
doaj
Optimising linezolid use for drug-resistant tuberculosis: pharmacokinetics, toxicity, and resistance [PDF]
, 2022 Background: Rifampicin-resistant tuberculosis (RR-TB) accounts for an expanding proportion of incident global TB cases and is a major barrier to global tuberculosis control. There is a need for more effective, safe, and well-tolerated drugs. Linezolid is
Wasserman, Sean Adam
core +1 more source
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies [PDF]
, 2018 Tuberculosis remains the world's leading cause of death from an infectious disease, responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of rifampicin-resistant tuberculosis in 2016-of which 490 000 were multidrug resistant
du Plessis, N +13 more
core +1 more source